secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-138249
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Q1 2024 net loss $63.2M; Phase 3 COVID trial enrollment complete, results due 2H 2024
--------------------------------------------------------------------------------

- Net loss $63.2M ($0.75 per share) vs $35.5M ($0.43) in Q1 2023.
- R&D expense nearly doubled to $57.6M, driven by Phase 3 SUNRISE-3 and Phase 2 HCV trials.
- Cash, equivalents, and marketable securities $541.5M, down $36.6M from year-end 2023.
- Phase 3 COVID trial fully enrolled (2,221 patients in monotherapy cohort); topline results expected 2H 2024.
- Phase 2 HCV lead-in cohort confirmed 98% SVR4; full Phase 2 results expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/0001193125-24-138249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/d798777d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer